Uveal Melanoma

Uveal Melanoma is a type of eye cancer. It starts in the uvea, which is the middle layer of the eye. This layer includes parts of the iris, ciliary body, and choroid. The cancer cells grow in this area, potentially affecting vision.

Condition

What people with Uveal Melanoma report

Every report comes from a Lived member, sent anonymously.

Have you had Brachytherapy for Uveal Melanoma?

NameHow it went

About Uveal Melanoma

What It Is

Uveal melanoma is a rare cancer that starts inside the eye, in the pigment-making cells of the uvea. The uvea is the eye's middle layer and has three parts: the iris (the colored ring at the front), the ciliary body just behind it, and the choroid, a layer of blood vessels beneath the retina. It is the most common cancer that begins inside the eye in adults. About nine in ten start in the choroid, which is why it is also called choroidal or ocular melanoma. Although it shares a name with skin melanoma, it behaves differently: its causes, genetic changes and response to treatment are not the same. Many people have no symptoms at first, and the tumor is often found during a routine dilated eye exam. When symptoms occur, they can include blurred or changing vision, new floaters or flashes of light, or a dark spot on the iris. The main concerns are the effect on the eye and vision, and the chance that the cancer spreads elsewhere in the body, most often to the liver.

Causes & Risk Factors

Most uveal melanomas occur by chance, from genetic changes that build up in the eye's pigment cells over a lifetime, and no single cause is known. Risk is higher with older age, a fair complexion (light skin that burns easily and blue, green or other light-colored eyes) and White ancestry. Unlike skin melanoma, sunlight has not been shown to cause melanoma at the back of the eye; the exception is iris melanoma, which has been linked to ultraviolet light. A small share, roughly 2 to 5 percent, runs in families, mainly through an inherited change in a gene called BAP1, which also raises the risk of some other cancers. Genetic counseling may be offered to people diagnosed young (under 40), with melanoma in both eyes, or with relatives who have had related cancers. Having a risk factor does not mean someone will develop this cancer, and many people who do have none.

How It's Diagnosed

An eye specialist, usually an ophthalmologist experienced with eye tumors, can typically diagnose uveal melanoma from what the tumor looks like. The exam involves widening the pupils with drops to look inside the eye, taking photographs, and using ultrasound to measure the tumor's height and width. Tumors behind the iris are imaged with a higher-resolution ultrasound. Unlike most cancers, a biopsy is usually not needed to confirm the diagnosis; it is considered when the appearance is uncertain, after discussing its risks, which include bleeding and retinal detachment. Once melanoma is diagnosed, the next steps judge the risk of spread. Doctors stage it by size, location and whether it has grown outside the eye; in one large analysis, the risk of spread within 10 years ranged from about 5 percent for the earliest stage to about 40 percent for more advanced stages. Tumor tissue from a biopsy or surgery can be tested for chromosome or gene changes (such as loss of chromosome 3 or a gene expression profile) that sort tumors into lower and higher risk groups. Imaging of the liver, by ultrasound or MRI, checks whether the cancer has already spread.

Treatment Options

Treatment of the eye tumor aims to control the cancer while keeping the eye, and as much vision as possible, when that can be done safely. The choice depends on the tumor's size and location, whether it has grown outside the eye, and personal preferences. Radiation is the most common eye-sparing treatment. In plaque brachytherapy, a small disc carrying radioactive seeds is stitched to the outside of the eye over the tumor for several days and then removed. Proton beam therapy aims a focused beam from outside the body. Both control the tumor in the eye very well. A large trial found that for medium-sized choroidal melanomas, plaque radiation led to the same long-term survival as removing the eye. The trade-off is that radiation side effects are common and can reduce vision in the treated eye over the following years, sometimes severely; regular injections into the eye are often used to help prevent abnormal blood vessel growth after treatment. Removing the eye (enucleation) is generally reserved for large tumors, tumors that have grown through the eye wall, or an eye that is already blind or painful; an artificial eye is fitted afterward. Small iris or ciliary body tumors can sometimes be cut out, and very small or uncertain lesions may be watched with photographs to confirm growth before treating. Treating the eye does not remove the risk of spread, because cancer cells may already have left the eye unseen. People at high risk may be offered a clinical trial of treatment after the eye is treated; no such added treatment is yet proven. If the cancer spreads, most often to the liver, the options are different from those for skin melanoma. Tebentafusp (Kimmtrak), a weekly intravenous immune treatment that directs the body's T cells to the melanoma, helped people live longer in a key trial (median survival about 22 months versus 17 with other drugs). It works only for people who carry a particular inherited immune tissue type, HLA-A*02:01, identified with a blood test. Its first three doses are given with at least 16 hours of monitoring afterward, because it can cause cytokine release syndrome, an immune reaction with fever and low blood pressure. For limited disease in the liver, surgery or tumor ablation may be possible. A liver-directed chemotherapy procedure that delivers melphalan straight to the liver (Hepzato Kit) is approved for some people with unresectable liver tumors; it can cause serious bleeding, clotting and blood count problems. Immune checkpoint drugs used in skin melanoma work much less often here, and clinical trials are an important option. Care at a center experienced in this rare cancer is recommended.

What to Expect

Most people are diagnosed while the cancer is still confined to the eye, and treatment usually controls the eye tumor. Life after treatment often involves adjusting to changes in vision in the treated eye, or to an artificial eye after enucleation. Eye checks continue every six months for the first few years, then yearly, to catch any regrowth or radiation effects early. The longer-term uncertainty is spread to the liver, which can appear many years after the eye is treated. The chance varies widely with tumor size and genetics, from small for low-risk tumors to as high as one in two for the highest-risk ones. Because of this, follow-up usually includes regular liver imaging for years, tailored to risk: for example, ultrasound every 6 to 12 months for at least five years in lower-risk cases, and MRI every 4 to 6 months for ten years or more in higher-risk cases. It is not yet proven that this surveillance helps people live longer, but it can find spread early enough for options such as surgery or trials. Living with this uncertainty is hard, and low mood is common after treatment; counseling and patient support groups for ocular melanoma can help.

When to Seek Help

Arrange a prompt eye exam with an eye doctor if you notice blurred vision or another change in vision that does not go away, new floaters or flashes of light, a dark spot on the iris, a change in the size or shape of a pupil, or a change in how the eye sits in its socket. These have many causes, but a dilated eye exam is the way to find out. If you have been treated, contact your eye or cancer team about any new change in vision or eye pain in the treated eye, and about any new symptom elsewhere in the body that does not settle, so the team can decide whether it needs checking. Keep to your planned eye checks and liver scans even when you feel well. During tebentafusp treatment, follow the care team's instructions about fever, dizziness or other reactions after an infusion.

Questions to Ask Your Doctor

  1. 1.Is my tumor suitable for eye-sparing treatment, and how is my vision likely to change with each option?
  2. 2.What do the stage and any genetic testing of my tumor say about my risk of spread?
  3. 3.What follow-up eye exams and liver scans do you recommend for my risk level, and for how long?
  4. 4.Should I be tested for HLA-A*02:01 or consider a clinical trial now or in the future?
  5. 5.Is this a center that treats many people with uveal melanoma, or should I be referred to one?

Last reviewed • Oct 2026

Educational content, not medical advice.